Nuwiq is approved by the Food and Drug Administration (FDA) to treat and prevent bleeding episodes in children and adults with hemophilia A (congenital factor VIII deficiency). The technical name of Nuwiq is Human coagulation factor VIII (rDNA), simoctocog alfa.

Nuwiq is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.

How do I take it?
Prescribing information states that Nuwiq is given as an intravenous injection.

Nuwiq comes as a powder that must be reconstituted before injection.

Side effects... read more

The FDA-approved label for Nuwiq does not list common side effects. Less commonly, Nuwiq may cause headache, dry mouth, vertigo, pins-and-needles sensations, back pain, and pain at injection site.

Rare but serious side effects listed for Nuwiq include life-threatening hypersensitivity reactions, complications involving the catheter of the central venous access device (CVAD), and the development of inhibitors.

For more details about this treatment, visit:


Treatment of Hemophilia – Hemophilia Federation of America

Continue with Facebook
Sign up with your email
Already a Member? Log in